Matches in Wikidata for { <http://www.wikidata.org/entity/Q66393817> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q66393817 description "clinical trial" @default.
- Q66393817 description "ensayu clínicu" @default.
- Q66393817 description "klinisch onderzoek" @default.
- Q66393817 description "клінічне випробування" @default.
- Q66393817 description "կլինիկական փորձարկում" @default.
- Q66393817 name "Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)" @default.
- Q66393817 name "Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease" @default.
- Q66393817 type Item @default.
- Q66393817 label "Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)" @default.
- Q66393817 label "Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease" @default.
- Q66393817 prefLabel "Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)" @default.
- Q66393817 prefLabel "Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease" @default.
- Q66393817 P1050 Q66393817-1159A9AB-4421-46E6-BF89-055F5F492565 @default.
- Q66393817 P1132 Q66393817-7C5C98E5-B674-43E6-8A04-3A7C13B57AF2 @default.
- Q66393817 P1476 Q66393817-91785BB1-46F9-41F2-AB21-BA1A820697CD @default.
- Q66393817 P17 Q66393817-39F732D5-4BD0-4198-80B1-4093141DDF56 @default.
- Q66393817 P17 Q66393817-4A404298-A7E2-4FE9-AA18-F522C73224E0 @default.
- Q66393817 P17 Q66393817-6464DC29-67F0-4A96-8474-994A0D1CEA06 @default.
- Q66393817 P17 Q66393817-7136E6D1-F901-458E-AE2B-9F4C60899B7C @default.
- Q66393817 P17 Q66393817-EC985260-C731-45E3-9F5D-FA7B13C30C2B @default.
- Q66393817 P2899 Q66393817-041986A8-BB5E-49FF-8708-9F2A03F1E688 @default.
- Q66393817 P3098 Q66393817-B52E950B-6986-455D-B2DA-63D617134ABC @default.
- Q66393817 P31 Q66393817-46C94F91-930E-4CA9-A59B-32A4248F72E4 @default.
- Q66393817 P4844 Q66393817-ABBDBBB3-A344-4343-A8A8-BB63CB47CEA4 @default.
- Q66393817 P580 Q66393817-33660A0A-4A91-4AF6-A31C-EA3ECCB9ABE2 @default.
- Q66393817 P582 Q66393817-66377452-B7F1-4EB0-BDD6-20809DA51E94 @default.
- Q66393817 P6099 Q66393817-4275B247-252A-4CE0-9942-A76ECAB5A709 @default.
- Q66393817 P8363 Q66393817-7282AD79-7B1C-4A45-871B-F6C93D823CD5 @default.
- Q66393817 P1050 Q394129 @default.
- Q66393817 P1132 "+111" @default.
- Q66393817 P1476 "A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease" @default.
- Q66393817 P17 Q142 @default.
- Q66393817 P17 Q145 @default.
- Q66393817 P17 Q29 @default.
- Q66393817 P17 Q298 @default.
- Q66393817 P17 Q30 @default.
- Q66393817 P2899 "+50" @default.
- Q66393817 P3098 "NCT02992132" @default.
- Q66393817 P31 Q30612 @default.
- Q66393817 P4844 Q7194603 @default.
- Q66393817 P580 "2016-11-01T00:00:00Z" @default.
- Q66393817 P582 "2018-01-25T00:00:00Z" @default.
- Q66393817 P6099 Q42824440 @default.
- Q66393817 P8363 Q78089383 @default.